← FDA DRUG APPROVALS

FDA BLA · BLA761411

NIKTIMVO

axatilimab-csfr

Sponsor: INCYTE CORP

APPLICATION
BLA761411
TYPE
BLA
ORIGINAL APPROVAL
2024-08-14
LATEST ACTION
2024-08-14
ROUTE
INTRAVENOUS
DOSAGE FORM
INJECTABLE
MARKETING STATUS
Prescription

Products

NIKTIMVOPrescription
axatilimab-csfr 50 MG/ML · INJECTABLE · INTRAVENOUS

Approval history

2024-08-14Type 1 - New Molecular Entity · Original · priorityLabelAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Biologics industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →